title: [Continuous glucose monitoring system (CGMS) in type 1 diabetic patients during 4 (96h) or 5 (120h) days: there is advantage?].
abstract: BACKGROUND
  To evaluate the accuracy, complications and impact in glycemic control in type 1 diabetic patients (DM1) submitted to 4 or 5 days of CGMS.
  
  
  METHODS
  We studied 36 DM1 patients (44.5%M/55.5%F), in three groups without no difference about age, DM duration and A1c levels (p < 0.05), submitted to 72h (G1), 96h (G2) and 120h (G3) CGMS profile. It were analyzed: capillary glycemia (CG) and mean CGMS sensors glycemic value; correlation coefficient, median absolute percent difference (MAD%), number of sensor reading, complications (trauma, local infection, disconnection, dropped), postprandial hyperglycemia, unrecognized hypoglycemia (< 70 mg/dl). A1c levels were measured at the start (1 month before) and after 3 and 12 months in each group.
  
  
  RESULTS
  No technical difference were observed into 3 groups: correlation coefficient > 0.79 and MAD < 28% in 95% (p < 0.01). The use of CGMS sensor more than 72h was not related to signal error, trauma, local infection or disconnection. The mean capillary glucose values showed no difference by glucose CGMS sensor (p = 0.01) in all groups. The nighttime episodes of hypoglycemia lasted longer (min) than daytime episodes in all groups (p = 0.05). The postprandial hyperglycemia was statistically identified in groups 1 and 3. This data showed significant decreased A1c level three months after the CGMS in G1 (72h) and G3 (120h) (p < 0.001 and p = 0.002, respectively), which sustained after 1 year (p < 0.001 e p = 0.047, respectively).
  
  
  CONCLUSIONS
  The CGMS showed to be a very safety method, with high accuracy/technical efficacy in patients undergoing 96 h and 120 h of CGMS. We do not observed advantages in the use of CGMS during 96 h or 120 h against 72 h in decrease A1c levels after 3 and 12 months. It is possible the use of CGMS > 72h, with no technical damage. However, we do not observed significant clinical benefits of this conduct in DM1 patients.
authors.affiliation: Departamento de Fisiologia, Faculdade de Ciências Médicas de Minas Gerais, Brasil. fredfrm@hotmail.com
authors.forename: Frederico F R
authors.initials: FF
authors.lastname: Maia
authors.forename: Levimar R
authors.initials: LR
authors.lastname: Araújo
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D015190:Blood Glucose Self-Monitoring / Q000379:methods* / Q000592:standards; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000628:therapy; D006801:Humans; D008875:Middle Aged; D018670:Monitoring, Ambulatory / Q000592:standards*; D010353:Patient Education as Topic; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001786:Blood Glucose